secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0000950170-24-013563
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar reports positive Phase 2 nomlabofusp data; frataxin dose response up to 5.57 pg/µg in skin
--------------------------------------------------------------------------------

- 50 mg cohort: median FXN increase in skin 5.57 pg/µg at day 14; all patients reached >33% healthy volunteer level.
- 25 mg cohort: median FXN increase in skin 2.81 pg/µg; one allergic AE resolved; 18 of 19 completed.
- Cash $86.8M as of Dec 31, 2023; expected runway into Q1 2025.
- OLE initiated Jan 2024 starting 25 mg daily; interim data expected Q4 2024.
- FDA discussions ongoing for accelerated approval using FXN as surrogate; BLA submission targeted 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024013563/0000950170-24-013563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024013563/lrmr-20240212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-013563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer